Therefore, antibodies (Bevacizumab, Aflibercept, and Ramucirumab) or tyrosine kinase inhibitors (Sorafenib, Sunitinib, Regorafenib, and Pazopanib) targeting VEGF pathways could be effective in high-risk gliomas patients with IDH mutations. This evidence concerns the gene IDH2 and glioma.